Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.58 |
| ▸ | NPY1R | P25929 | 7/20 | 0.58 |
| ▸ | NPY2R | P49146 | 5/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.58 |
| ▸ | KISS1R | Q969F8 | 6/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29464013 | 0.97 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL29540098 | 0.95 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL23405252 | 0.94 | NPY4R (0.64) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL23405249 | 0.94 | NPY4R (0.64) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL30570978 | 0.93 | KISS1R (0.56) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL31222396 | 0.93 | NPY4R (0.66) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL29520335 | 0.92 | NPY4R (0.64) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL31415959 | 0.91 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL31415960 | 0.91 | NPY4R (0.58) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL30900089 | 0.91 | NPY4R (0.66) | NPY4RNPY1RNPY2RNPY5RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152205-A1 | MODULATING PERMEABILITY OF THE BLOOD CEREBROSPINAL FLUID BARRIER | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-05-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152205-A1 | MODULATING PERMEABILITY OF THE BLOOD CEREBROSPINAL FLUID BARRIER | C3AR1, CFH, CSF3R | NPY4R 1578/4885NPY1R 1590/4885NPY2R 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.